Dennis Lanfear is a pioneer and leader within the biotechnology industry with a track record for entrepreneurial vision and accomplishment. Most recently as the founding President, CEO and Chairman of Coherus BioSciences, he has advanced Coherus from its inception in 2010 into a publically traded organization widely regarded as the leading pure play biosimilar company for the major regulated markets. His vision for improved access to high quality, life-changing medicines has led to the development of a late stage pipeline of biosimilar candidates for the treatment of inflammatory diseases and oncology, strategic collaborations with Daiichi Sankyo and Baxter International , the financial strength of over $220M in private financing, and $81.5M in net proceeds associated with the Company’s Initial Public Offering in November 2014, and the creation of talented organization of leading drug developers.
Mr. Lanfear has nearly 30 years of biopharmaceutical business experience in technical and leadership roles. He is a 13-year veteran of Amgen. where he was a Corporate Officer and Vice President with broad operational, product development and marketing responsibility. His tenure began in 1986 as a founder of the Process Development Department. Under his 10-year leadership, this group became the preeminent process development organization in biopharmaceuticals and a key strategic advantage for the company. As Vice President of Process Development and Operations Systems, he directed the business process integration of more than 2,500 operations and quality staff worldwide.